The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $50.78

Today's change+0.44 +0.87%
Updated November 26 3:13 PM -5GMT. Delayed by at least 15 minutes.
 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $50.78

Today's change+0.44 +0.87%
Updated November 26 3:13 PM -5GMT. Delayed by at least 15 minutes.

Powershares Dynamic Biotechnology and Genome Portfolio up (U.S.)$0.44

Powershares Dynamic Biotechnology and Genome Portfolio is up today by (U.S.)$0.44 or 0.87% to (U.S.)$50.78. Over the last five days, shares have gained 2.66% and 37.05% year to date. Shares have outperformed the S&P 500 by 20.34% during the last year.

Key company metrics

  • Open(U.S.) $50.28
  • Previous close(U.S.) $50.34
  • High(U.S.) $50.83
  • Low(U.S.) $50.28
  • Bid / Ask(U.S.) $50.76 / (U.S.) $50.80
  • YTD % change+37.05%
  • Volume34,236
  • Average volume (10-day)49,171
  • Average volume (1-month)55,424
  • Average volume (3-month)49,265
  • 52-week range(U.S.) $35.12 to (U.S.) $51.07
  • Beta1.07
  • Trailing P/E6.43×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.28
  • Dividend yield0.55%
  • Trailing EPS(U.S.) $7.90
Updated November 26 3:13 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+3,649.42%

Based on its net profit margin of 3,649.42%, Powershares Dynamic Biotechnology and Genome Portfolio is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.21%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q2/2014Q4/2013Q2/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedApr 30, 201404/30/2014Oct 31, 201310/31/2013Apr 30, 201304/30/2013Oct 31, 201210/31/2012
Revenue2000
Total other revenue--------
Total revenue2000
Gross profit1000
Total cost of revenue1000
Total operating expense1100
Selling / general / administrative0000
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income0000
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax2740330
Income after tax2740330
Income tax, total0000
Net income2740330
Total adjustments to net income--------
Net income before extra. items2740330
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2740330
Inc. avail. to common incl. extra. items2740330
Diluted net income2740330
Dilution adjustment----00
Diluted weighted average shares11756
Diluted EPS excluding extraordinary itemsvalue per share2.545.376.230.06
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share2.545.37-0.03-0.02